KI 1115
Alternative Names: KI-1115Latest Information Update: 12 Oct 2021
At a glance
- Originator Kuhnil Pharmaceutical Company
- Class Anticoagulants
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Iron overload
Most Recent Events
- 07 Oct 2021 Launched for Iron overload in South Korea (unspecified route) (Kuhnil Pharmaceutical company)